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A  central  problem  in tumor immunology is to explain  why immunogenic tumors 
grow progressively in  their  immunocompetent  syngeneic hosts.  Attempts  to explain 
this paradox have included suggestions that (a) the weakness of tumor transplantation 
antigens allows tumors to sneak through immune surveillance  (1);  (b) tumor cells are 
capable  of hiding  their  surface  antigens  from  immune  effector  mechanisms  by  a 
process  known  as  antigenic  modulation  (2,  3);  (c)  tumors  induce  the  generation  of 
soluble antibody-dependent blocking factors that specifically block the cytotoxicity of 
effector lymphocytes (4); and (d) tumor growth favors the generation of suppressor T 
cells (5-13). 
The paradox of progressive growth of immunogenic tumors  is well  illustrated  by 
examples  of concomitant  anti-tumor  immunity,  in which  a  host with  a  progressive 
tumor can specifically suppress the growth of cells of the same tumor implanted at a 
distant  site  (14).  It has been documented,  moreover, that concomitant  immunity to 
some tumors  undergoes  progressive decay after  the primary tumors  reach  a  certain 
critical  size  (14-20).  Indeed,  a  recent  study in this  laboratory  (21,  22)  of the T-cell- 
mediated  nature  of endotoxin-induced  tumor regression  revealed  that  concomitant 
immunity generated  against  one of the tumors under study, the chemically induced 
Meth  A  fibrosarcoma,  underwent  a  process  of rapid  decay  very  soon  after  it  was 
generated. It was further shown that the onset of decay of concomitant immunity was 
coincident with the onset of refractoriness of this tumor to endotoxin-induced regres- 
sion. The possibility was revealed, therefore, that a  suppressor mechanism causes the 
loss  of concomitant  immunity  to  the  Meth  A  fibrosarcoma,  and  that  the  same 
mechanism is responsible for causing this tumor to lose its susceptibility to endotoxin 
immunotherapy. 
The purpose of this paper is to provide evidence consistent with the hypothesis that 
concomitant immunity to the Meth A fibrosarcoma decays as a result of the generation 
of a  mechanism  of T-cell-mediated  immunosuppression.  Two  main  findings  are 
presented.  First, that it is possible to cause the complete regression of large established 
tumors by intravenous infusion of sensitized T  cells from immune donors, but only if 
the tumors are growing in thymectomized T-cell-deficient recipients. Second, that the 
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adoptive T-cell-mediated regression of established tumors in T-celt-deficient recipients 
can be inhibited by an infusion of splenic T  cells from T-cell-intact, tumor-bearing 
donors that have lost their concomitant immunity. These and other findings suggest 
that  failure of the immune system to reject this immunogenic tumor is the result of 
the generation of suppressor T  cells. 
Materials and Methods 
Mice.  CB6 (BALB/c x  C57BL/6)Fx mice of either sex were used when they were between 
8 and 10 wk of age. They were produced and reared under barrier-sustained conditions in the 
Trudeau Institute Animal Breeding Facility from caesarean-derived, conventionalized  parental 
BALB/c and C57BL/6 breeding stock originally obtained from The Jackson Laboratory, Bar 
Harbor, Maine. All mice were shown to be free of known infectious viruses, including lactic 
dehydrogenase virus. 
Tumors.  The methylcholanthrene-induced  Meth A fibrosarcoma syngeneic in BALB/c mice 
was originally  obtained from Dr. Lloyd J. Old of the Memorial Sloan-Kettering  Cancer Center, 
New  York.  This  tumor  possesses  a  distinct surface  transplantation antigen that  has  been 
serologically defined (23). It was obtained in the ascites form, and grown in culture in Fischer's 
medium (Grand Island Biological  Co., Grand Island, N.  Y.)  for several weeks  before being 
grown again in the  ascites  form in syngeneic BALB/c mice. Tumor cells  thus grown were 
dispensed into a large number of small vials, biofrozen in Fischer's medium that contained 20% 
fetal bovine serum and 20% dimethylsulfoxide, and cryopreserved over liquid nitrogen. Before 
each experiment, a vial was thawed and the cells washed in phosphate-buffered saline (PBS), x 
and grown intraperitoneally in semisyngeneic CB6 mice. The cells were harvested from CB6 
mice, washed in PBS, and resuspended appropriately in PBS for implantation, either intrader- 
mally in the belly region or subcutaneously in the plantar region of the right-hind footpad. 
Intradermal tumor growth was measured by excising and weighing the tumors of five mice at 
the times indicated. Footpad tumor growth was monitored by measuring changes against time 
in the dorsoventral thickness of the footpad with dial calipers. 
The SA-1 fibrosarcoma syngeneic in A/J mice was used as an allograft. It was grown in vitro 
and passaged in A/J mice in the same way as described for the Meth A. 
T-Cell-deficient  Mice.  Mice were made T-cell deficient by thymectomy (THXB) at 3 wk of 
age followed  7 d later by 900 rads of whole-body gamma irradiation delivered from a cesium- 
137  irradiator at  a  midphantom dose  rate  of 35.5  rads/min. They were  infused with  106 
syngeneic bone marrow cells within 2 h  of irradiation and employed in experiments after a 
further 4-5 wk. 
Adoptive Immunization.  The donors of tumor-sensitized  T cells were mice that had been made 
specifically immune to a Meth A challenge implant by causing their 6-d intradermal tumors to 
completely regress  by intravenous infusion of 50  #g  of endotoxin (21).  Their spleens were 
removed 10 d after tumor regression,  diced into small pieces, and gently pushed through a 200- 
mesh stainless steel screen into PBS that contained 1% heat-inactivated fetal bovine serum. The 
suspension was triturated with a Pasteur pipette to break up clumps, and passed through six 
layers of sterilized surgical gauze. The cells were washed and resuspended at an appropriate 
concentration in PBS for intravenous infusion. Spleen cells from tumor-bearing donors and 
from normal donors were prepared in the same way. 
The recipients of tumor-sensitized spleen cells were T-cell-deficient mice and age-matched, 
control mice carrying either intradermal or footpad tumors initiated 4 or 6 d  earlier by the 
implantation of 1 X 108 or 2 X  10  s tumor ceils. 
Antiserum.  Anti-Thy-1.2 serum was produced in AKR mice immunized with C3H thymo- 
cytes. The serum was absorbed with AKR thymocytes and its specificity tested by adsorption 
with brain tissue as described previously (24). Spleen cells were incubated at 5 ×  107/ml  in a 
1:5  dilution of the  antiserum for  30  min on ice.  The cells  were  then washed  in PBS  and 
incubated for  30  min at  37°C  in the  same  volume of a  1:5  dilution of agarose-absorbed, 
noneytotoxic guinea pig serum. They were then washed in PBS and prepared for intravenous 
infusion. 
1 Abbreviations used in this paper: PBS, phosphate-buffered  saline; THXB, T-cell deficient by thymectomy. I,$- 
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FIG.  1.  Evidence  that it is not possible to cause regression of an established intradermal Meth A 
tumor by intravenous infusion (arrow) of sensitized  T cells from immune donors, unless the tumors 
are growing in THXB recipients. Infusion of 1.5 X 108 sensitized spleen cells into THXB recipients 
resulted in the onset of tumor regression after an ~  7-d delay and caused complete rejection of the 
tumors after a further 7 d. Means of five mice per time interval. 
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Concomitant Immunity.  Mice carrying intradermal or footpad tumors were tested against time 
of tumor growth for the acquisition of resistance to growth of a standard 1 ×  106 tumor cell 
challenge implant given in the left-hind footpad. Growth of the challenge implant was measured 
against time with dial calipers. Immunity is expressed  as the difference between the size of the 
implant in control mice and tumor-bearing mice 8 d after challenge. 
Results 
Need for  T-Cell-deficient  Recipients  to  Demonstrate Adoptive  Immunity  against  Established 
Tumors.  Whereas published descriptions of the adoptive transfer of immunity against 
growth of implanted tumor cells are relatively numerous, descriptions of the expression 
of adoptive immunity against already established tumors are almost nonexistent (25). 
The purpose of the results described in this section is to show that failure of passively 
transferred, sensitized T  cells to cause regression of established Meth A fibrosarcomas 
is  caused  by  the  presence  in  the  tumor-bearing recipients of a  thymus-dependent 
mechanism of immunosuppression. 
Fig.  1 shows the results of an experiment in which an attempt was made to regress 
established  6-d  intradermal  tumors  growing  in  T-cell-intact and  T-cell-deficient 
recipients by the intravenous infusion of spleen cells from immune donors. The donors 
were made specifically immune to growth of a tumor implant by causing their tumors 
to  completely regress  by  endotoxin therapy  10  d  earlier  (21).  It  can  be  seen  that 
whereas  an  infusion of immune spleen  cells  had  no  effect  on  established  tumors 
growing in T-cell-intact recipients, the same number of immune spleen cells caused 
dramatic regression of large established tumors growing in T-cell-deficient recipients. 
It will be noted, moreover, that there was an ~  7-d delay before the onset of regression, 
but that once the regression process commenced it was rapid and complete. An idea 
of the  size of the  established tumors that  were caused  to  regress  in T-cell-deficient 
recipients by passive transfer of immune spleen cells can be gauged from an exami- 
nation of Fig. 2. 
Direct Evidence that  Tumor-bearing Mice Possess Suppressor Cells.  The foregoing results 
show  that  mice  bearing established  Meth  A  tumors  acquire  a  thymus-dependent 
mechanism that prevents their tumors from being regressed by an infusion of sensitized 72 M. J.  BERENDT  AND R. J.  NORTH  73 
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F[~.  3.  Evidence that T-ceil-intact, tumor-bearing mice contain spleen cells that can prevent the 
expression of adoptive cell-mediated regression of established tumors in THXB recipients.  On day 
6 of tumor growth (arrow)  THXB tumor bearers were infused intravenously with 1.5 ×  l0  s spleen 
cells from donor mice bearing 15-d tumors, and infused  4 h later with the same number of spleen 
cells from immune donors. It is obvious that prior infusion of spleen cells from tumor-bearing donors 
prevented immune spleen cells from causing tumor regression. Means of five mice per time interval. 
lymphocytes from immune donors. The purpose of the experiments in this section is 
to show that  this  thymus-dependent suppressor  mechanism can be passively trans- 
ferred to T-cell-deficient recipients with spleen cells from tumor-bearing  donors. 
It can be seen in Fig. 3 that  prior  (4 h)  intravenous  infusion of spleen cells from T- 
cell-intact  donors  bearing  15-d  intradermal  tumors  prevented  an  infusion  of spleen 
cells from  immune  donors  from  regressing  established  intradermal  tumors  in T-cell- 
deficient  test  recipients.  Fig.  4  shows  the  results  of an  identical  experiment,  except 
that  in  this  case,  the  test  tumors  were  growing  subcutaneously  in  the  right-hind 
footpad.  It  can  be  seen,  in  both  experiments,  that  normal  spleen  cells  possessed  no 
detectable  suppressor  activity according to  this assay.  Suppressor  ceils alone had  no 
effect on tumors growing in either T-cell-intact or T-cell-deficient recipients (evidence 
not shown). 
Evidence  that the Mechanisms of Regression  and Suppression  are Mediated by T  Cells.  The 
results in Table I  show that  the spleen cells from immune  donor mice, which mediate 
regression of established  tumors  in T-cell-deficient test recipients, like the spleen cells 
from  T-cell-intact,  tumor-bearing  donors,  which  suppress  the  mediation  of  this 
regression,  were  destroyed  by incubation  with  anti-Thy-l.2  serum  and  complement. 
Table  I  also  shows  that  intravenous  infusion  of 0.5  ml  of serum  from  the  tumor- 
bearing donors  of suppressor  cells had  no effect on the expression of adoptive T-cell- 
FIG.  2.  Photographic  demonstration  of  the  model  of  adoptive  T-cell-mediated  regression  of 
established  tumors used in this study.  Both groups  of mice received an intravenous infusion  of 1.5 
×  10  s spleen ceils from immune donors on day 6 of tumor growth.  The mice were photographed  12 
d later. Tumors in the three T-cell-intact recipients at the top of the picture continued to grow. In 
contrast,  tumors  in the three  thymectomized T-cell-deficient mice at  the bottom  of the picture 
dramatically regressed. Regression  commenced ~  7 d after passive transfer of spleen cells, by which 
time the tumors had reached a large size. The remaining scab sloughed off after a further 2-3 d. 74  T-CELL  SUPPRESSION  OF  ANTI-TUMOR  IMMUNITY 
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FIG. 4.  Additional  evidence  that  spleen  cells  from  tumor-bearing donors cause  suppression of 
adoptive T-cell-mediated  regression of established tumors in T-cell-deficient  recipients. The exper- 
imental design was the same as that  described for Fig.  3, except  that  in this case the test  tumors 
were growing in the right-hind footpad. This avoided the need to sacrifice  mice to excise and weigh 
their tumors, and allowed the same tumors to be measured repeatedly throughout the course of the 
experiment. Means of five mice per time interval. 
TABLE  I 
Effect of Anti- Thy- 1.2 Serum on the Effectors and Suppressors of Adoptive T-Cell- 
mediated Tumor Regression in THXB Recipients 
No. corn- 
Spleen cells infused intravenously on  Tumor weight 14 d after  plete regres- 
sions at 
day 6  cell transfer (mean --- SE)  time of ex- 
cision 
g 
Normal cells  2.41 +  0.089  0/7 
Immune cells  0.095  +  0.015  3/5* 
Thy- 1.2-treated  immune cells  2.16 +_ 0.198  0/5 
Immune cells +  suppressor cells  1.45 __. 0.156:~  0/7:~ 
Immune  cells  +  Thy-l.2-treated  0  7/7 
suppressor cells 
Immune  cells  +  0.5  ml  of  serum  0.076  4/5* 
from suppressor donors 
1.5 ×  l0  s anti-Thy-l.2-treated spleen cells or untreated spleen cells from immunized 
donors and/or from donors with progressive 15-d tumors (suppressor donors) were 
infused intravenously into THXB test  recipients with 6-d established intradermal 
tumors. Tumors were excised  and  weighed  14  d  later  when tumor regression in 
appropriate experimental groups was on the way to completion. 
* Previous experiments indicate that all  tumors in these regressor groups would have 
completely regressed over the next 7 d. 
:~ At  the  time of excision,  the  tumors in recipients that  received  immune cells  plus 
suppressor cells  were growing at  the same rate  as tumors in  recipients of normal 
spleen cells  (Fig.  3). 
mediated  tumor  regression.  These  results  leave  little  doubt,  therefore,  that  T  cells 
were responsible for mediating  regression and  for suppressing  regression. 
Evidence  that  Concomitant  Immunity  to  the  Meth  A  Fibrosarcoma  Decays  Soon after  It  is 
Generated.  The  purpose  of this section  is to show  that  although  an  immune  response M.  J.  BERENDT  AND  R.  J.  NORTH 
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FIG.  5.  Evidence that concomitant immunity generated against the Meth A fibrosarcoma under- 
goes progressive decay  at  an  early  stage of tumor  growth.  Shown  are  changes in  concomitant 
resistance to growth of a standard challenge of 1 ×  l0  s Meth A tumor cells implanted in the right- 
hind  footpad  at  progressive  stages  of growth  of an  intradermal  primary  tumor.  Concomitant 
immunity is expressed as the difference between the size of the challenge implant in normal mice 
and its size in tumor-bearing mice 8 d  after challenge. Means of five mice per time point. 
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to  the  Meth  A  fibrosarcoma  is  generated  at  an  early stage  of tumor  growth,  the 
immunity is either progressively suppressed or decays soon after. 
The kinetics of generation and decay of concomitant immunity during intradermal 
growth of the Meth A  fibrosarcoma is shown in Fig.  5. The results are recorded as 
changes  against  time of growth  of the  primary tumor  in  the  level of resistance to 
growth of a standard  106 challenge implant given in the right-hind footpad. It can be 
seen that concomitant immunity was generated rapidly, peaked at about day 4, and 
then underwent progressive decay, until about day 16 when immunity to the challenge 
implant was no longer expressed. It is evident, therefore, that the donors of suppressor 
T  cells in the foregoing experiments were employed at a stage when their concomitant 
immunity had been completely suppressed. 
Specificity.  To properly investigate the specificity of suppression would require the 
possession of a syngeneic tumor with similar immunogenic properties to the Meth A 
fibrosarcoma. The possibility that one or more such tumors is present in our tumor 
hank is being investigated. However, an estimate of whether or not the suppressor T 
cells generated in response to progressive growth of the Meth A can cause a state of 
generalized  immunosuppression  can  be obtained by determining whether Meth  A 
tumor bearers  are  deficient in  their capacity to reject a  tumor  allograft.  This was 
investigated  by  following the  growth  of  l0  s  allogeneic  SA-1  sarcoma  cells  (H-2  ") 
implanted  in  the  right-hind  footpad  of CB6  (H-2  d  ×  H-2  b)  mice  carrying  9-d 
intradermal Meth A tumors. 
It can be seen in Fig. 6 that CB6 mice carrying large progressive Meth A  tumors 
were not deficient in their capacity to reject the SA-1 allograft after it had grown to 
an  appreciable  size.  In  fact,  Meth  A  tumor  bearers  showed  more  anti-allografl 
resistance than control mice, probably because of the presence of a Meth A-induced, 
activated  macrophage  system  (22).  Thus,  this  evidence  shows  that  the  T  cells 76  T-CELL SUPPRESSION  OF ANTI-TUMOR  IMMUNITY 
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Fro. 6.  Evidence that a large progressive intradermal Meth A tumor does not suppress the capacity 
of the host to reject a tumor allograft. In this experiment  intradermal belly tumors were initiated 
with 2 ×  10  6 Meth A cells, and the hosts injected with  10  6 SA-1 cells in the right-hind footpad on 
day 9 of Meth A growth. If anything,  the Meth A bearers were more capable than controls of 
generating  and expressing immunity to the allograft after it had grown progressively for ~  6 d. 
Means of five mice per time interval. 
responsible for suppressing anti-Meth  A  immunity  do not  suppress  the capacity to 
generate and express cell-mediated immunity in general. 
Discussion 
The results of this paper provide an explanation for why the highly immunogenic 
Meth  A  fibrosarcoma is not  rejected by its immunocompetent  syngeneic host.  The 
findings  are  consistent  with  the  hypothesis  that  progressive  growth  of this  tumor 
causes  the generation  of a  population  of T  cells that  functions  to prevent  the host 
from  generating a  protective level of anti-tumor immunity.  It was shown  first, that 
passively transferred, sensitized T  cells from immunized donors fail to cause regression 
of established  tumors,  unless  the  tumors  are  growing  in  recipients  that  have  been 
made  T-cell  deficient  by  thymectomy  and  irradiation,  and  protected  with  bone 
marrow.  It was  shown  next, that  adoptive T-cell-mediated regression of established 
tumors in T-cell-deficient recipients can be prevented by prior infusion of splenic T 
cells from  T-cell-intact, tumor-bearing donors.  It follows, therefore, that  the tumor- 
bearing  donor  mice  acquired  a  tumor-induced  state  of T-cell-mediated  immuno- 
suppression.  Hence, the reason for the progressive decay of an earlier acquired state 
of T-cell-mediated concomitant anti-tumor immunity. 
The results also suggest the reason for the paucity of published demonstrations of 
regression of established tumors by passively transferred sensitized T  cells (25). Indeed, 
it is easy to demonstrate adoptive T-cell-mediated immunity to growth of implants of 
the Meth A  fibrosarcoma in normal recipients (21), provided the passive transfer of 
sensitized T  cells is not delayed more than 3-4 d  after tumor cell implantation. After 
this time the tumor becomes completely refractory to the effects of the infused T  cells. 
It is obvious, therefore,  that  the generation of suppressor T  cells begins at  an  early 
stage of tumor growth, but not before the host generates a  transitory state of T-cell- 
mediated  immunity,  as  evidenced  by  the  curve  for  the  generation  and  decay  of 
concomitant immunity. In fact, the evidence revealed here about the host response to 
the Meth A  fibrosarcoma is in keeping with the prediction (26)  that  negative T-cell 
regulation of the immune response is always preceded or accompanied by positive T- M. J.  BERENDT AND R. J.  NORTH  77 
cell regulation,  presumably because the generation  of the former relies on feedback 
signals  from the  latter  (27,  28).  It is  also apparent  that  the  response to this  tumor 
resembles  the  induction  of high-zone  tolerance,  where  it  has  been  shown  that  a 
transitory immune response, more often than not, precedes the onset of the state of 
immunological unresponsiveness (29). There is little doubt, moreover, that this type 
of immunological tolerance is mediated by suppressor T  cells (30,  31). 
Presumably,  then,  the  increase  in  the  quantity  of tumor-specific transplantation 
antigen that results from progressive tumor growth resembles the antigen overloading 
conditions  required  for  the  induction  of high-zone  tolerance.  It  seems  reasonably 
clear, therefore, that any attempt to cause the regression of an established  immuno- 
genic  tumor  by  passively  transferring  sensitized  T  cells  represents  an  attempt  to 
abrogate immunological tolerance in a recipient that is receiving tolerance-sustaining 
doses of antigen.  Because attempts to break tolerance to antigens by passive transfer 
oflymphocytes is difficult to achieve, it is not surprising that published demonstrations 
of the regression of established tumors by the passive transfer of sensitized T  cells are 
rare (25). 
Immunological  tolerance  can  be  broken,  however,  by  the  passive  transfer  of 
lymphocytes into recipients that have been x-irradiated (32), and high-zone tolerance 
in general is known to decay after the antigenic stimulation  is discontinued  (29).  It 
was not surprising to find, therefore, that T-cell-mediated suppression induced by the 
Meth  A  fibrosarcoma resembles high-zone  tolerance  in  both of these respects.  It  is 
known,  in the first place, that x-irradiated Meth A  tumor bearers can substitute  for 
T-cell-deficient tumor bearers for demonstrating that passively transferred sensitized 
T  cells  (and,  to a  lesser extent,  normal T  cells)  can cause regression of established 
tumors (M. J. Berendt and R. J. North. Manuscript in preparation.). It is also known 
that  removal of the tumor antigen  load by surgical excision of established  Meth  A 
tumors  results,  in  <  2  wk,  in  the emergence of specific immunity to the growth of 
implants  of  this  tumor  (21).  Because  tumor  excision  and  subsequent  tumor  cell 
challenge is a classical technique for demonstrating the immunogenicity of transplant- 
able tumors, it seems highly likely that other tumors shown to be immunogenic by 
this  method  will  be  found  to  resemble  the  Meth  A  fibrosarcoma in  terms  of its 
capacity to evoke the generation of suppressor T  cells. 
Direct  evidence that  immunogenic tumors induce  the  generation  of functionally 
dominant  numbers  of suppressor T  cells  has been  published  by others  (8-13).  We 
believe, however, that  the suppressor model revealed  by this study  is exceptionally 
convincing, by virtue of the fact that suppression can be measured against a  mecha- 
nism of T-cell-mediated immunity powerful enough to cause the regression of large, 
established  tumors.  We  are  aware,  nevertheless,  that  the  model  contains  many 
unknowns. It is not known at this stage, for example, whether the passively transferred 
T  cells that cause tumors to regress in T-cell-deficient recipients are cytolytic T  cells 
or memory T  cells. Again, the delay before infused suppressor T  cells allow tumors to 
completely escape from adoptive immunization  (Figs.  3 and 4)  suggests some inter- 
esting mechanistic possibilities. 
Perhaps  the  most  important  unknown,  however,  is  whether  the  mechanism  of 
suppression  is  specific  or  nonspecific.  A  proper  investigation  of this  problem  will 
require  a  syngeneic,  immunogenic  tumor  that  gives  rise  to  the  same  type of host 
response as the Meth A. This would allow a  direct  determination of whether the T 78  T-CELL SUPPRESSION OF ANTI-TUMOR  IMMUNITY 
cells that  suppress adoptive T-cell-mediated regression of the Meth  A  also suppress 
adoptive T-cell-mediated regression of an immunogenically similar tumor, and vice 
versa. We are certain at this stage, however, that growth of the Meth A fibrosarcoma 
does not cause a generalized state ofimmunosuppression, as evidenced by the findings 
that  mice bearing this  tumor are capable of generating T-cell-mediated immunity 
against, and of causing regression of, a  large tumor allograft. They are also capable 
of generating and expressing T-cell-mediated immunity against the bacterial patho- 
gen, Listeria monocytogenes (M. J. Berendt and R. J. North. Manuscript in preparation.). 
It can be suggested in conclusion that the acquisition of a  tumor-induced state of 
T-cell-mediated immunosuppression  is  almost certainly responsible for the onset  of 
refractoriness  of the  Meth  A  fibrosarcoma to  endotoxin-induced  regression,  as  de- 
scribed in previous reports  (21,  22).  Therefore, the possibility that the emergence of 
functionally dominant  numbers of suppressor T  cells is responsible for the onset  of 
resistance of this  and  other tumors to the effects of commonly employed immuno- 
therapeutic  agents,  such  as  Bacillus  Calmette-Gu~rin  and  Co~ynebacterium parvum, 
should be considered, 
Summary 
The results of this paper are consistent with the hypothesis that progressive growth 
of the Meth A fibrosarcoma evokes the generation of a T-cell-mediated mechanism of 
immunosuppression that prevents this highly immunogenic tumor from being rejected 
by its immunocompetent host. It was shown that it is possible to cause the regression 
of large, established  Meth  A  tumors by intravenous  infusion  of tumor-sensitized T 
cells  from  immune  donors,  but  only  if the  tumors  are  growing  in  T-cell-deficient 
recipients.  It was also shown that the adoptive T-cell-mediated regression of tumors 
in such recipients can be prevented by prior infusion of splenic T  cells from T-cell- 
intact,  tumor-bearing  donors.  The  results  leave  little  doubt  that  the  presence  of 
suppressor T  cells in T-cell-intact, tumor-bearing mice is responsible for the loss of an 
earlier generated state of concomitant immunity, and for the inability of intravenously 
infused, sensitized T cells to cause tumor regression. Because the presence of suppressor 
T  cells generated in response to the Meth A did not suppress the capacity of Meth A- 
bearing mice to generate and express immunity against a tumor allograft, it is obvious 
that they were not in a state of generalized immunosuppression. 
The  authors  wish  to  gratefully  acknowledge  the  excellent  technical  assistance  of Mr.  T. 
Arsenault, Mr. D. Kirstein, Ms. D. Klock, Mr. E. Krehl, and Ms. J. Wright, and the excellent 
secretarial assistance  of Mrs. Nancy Tuthill. 
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